NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of the Safety and Efficacy of Synvisc and Depo-Medrol in Patients With Osteoarthritis of the Hip

CompletedPhase 3

Sponsor: Genzyme, a Sanofi Company

Conditions: Osteoarthritis, Hip, Musculoskeletal Diseases

Interventions: Synvisc (hylan G-F 20)

Countries: United States

This is a clinical study to investigate the safety and efficacy of Synvisc and Depo-Medrol in treating patients with osteoarthritis (OA) of the hip.

Eligibility overview

Sex: ALL

Age: 35 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Patients with symptomatic osteoarthritis pain of hip

Exclusion Criteria:

* Patients with current or prior conditions or treatment that would impede measurement of efficacy and safety

Locations (32)

Birmingham, Alabama, United States
Huntsville, Alabama, United States
Scottsdale, Arizona, United States
Little Rock, Arkansas, United States
Los Angeles, California, United States
Oakland, California, United States
San Diego, California, United States
Clearwater, Florida, United States
Miami, Florida, United States
Columbus, Georgia, United States
Meridian, Idaho, United States
Chicago, Illinois, United States
Morton Grove, Illinois, United States
Cedar Rapids, Iowa, United States
Leawood, Kansas, United States
Lexington, Kentucky, United States
Shreveport, Louisiana, United States
Baltimore, Maryland, United States
Flint, Michigan, United States
St Louis, Missouri, United States
New Brunswick, New Jersey, United States
New York, New York, United States
Oklahoma City, Oklahoma, United States
Grants Pass, Oregon, United States
Duncansville, Pennsylvania, United States
Lancaster, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Conway, South Carolina, United States
Chattanooga, Tennessee, United States
Lubbock, Texas, United States
+ 2 more on CT.gov